Trends in human papillomavirus (HPV) vaccination initiation among adolescents aged 13-17 by metropolitan statistical area (MSA) status, National Immunization Survey - Teen, 2013 - 2017.


Journal

Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652

Informations de publication

Date de publication:
03 03 2020
Historique:
pubmed: 31 10 2019
medline: 22 6 2021
entrez: 31 10 2019
Statut: ppublish

Résumé

Disparities in HPV vaccination coverage by metropolitan statistical area (MSA) status were observed in the 2016 and 2017 National Immunization Survey - Teen (NIS-Teen). In 2017, HPV vaccination initiation (≥1dose) coverage was 11 percentage points lower for adolescents living in non-MSAs (mostly rural areas) and 7 percentage points lower among those living in MSA, non-principal cities (suburban areas) compared to those living in MSA, principal cities (mostly urban areas). In order to understand how this disparity has changed over time, we examined trends in HPV vaccine initiation by MSA status from 2013 to 2017. Weighted linear regression by survey year was used to estimate annual percentage point changes in HPV vaccination initiation. The five-year average annual percentage point increases in HPV vaccination initiation coverage were 5.2 in mostly urban areas, 4.9 for suburban areas, and 5.2 for mostly rural areas. Despite increases in each MSA area, coverage in mostly rural areas was consistently and significantly lower than coverage in mostly urban areas. Coverage was significantly lower among teens living in mostly rural areas regardless of poverty status, sex, and race/ethnicity except among black, non-Hispanic adolescents. There was no significant change in the magnitude of the disparity between mostly urban areas and mostly rural areas over time (

Identifiants

pubmed: 31662024
doi: 10.1080/21645515.2019.1671765
pmc: PMC7227639
doi:

Substances chimiques

Papillomavirus Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

554-561

Références

Pediatrics. 2017 Jan;139(1):
pubmed: 27940512
BMC Public Health. 2017 Jul 14;18(1):19
pubmed: 28709420
Pediatrics. 2016 Feb;137(2):e20152488
pubmed: 26729738
Am J Public Health. 2013 Jan;103(1):164-9
pubmed: 22698055
MMWR Morb Mortal Wkly Rep. 2018 Aug 24;67(33):909-917
pubmed: 30138305
Matern Child Health J. 2016 Feb;20(2):315-25
pubmed: 26511129
Prev Med. 2018 Apr;109:39-43
pubmed: 29378268
MMWR Morb Mortal Wkly Rep. 2017 Aug 25;66(33):874-882
pubmed: 28837546
J Natl Cancer Inst. 2015 Apr 29;107(6):djv086
pubmed: 25925419
MMWR Morb Mortal Wkly Rep. 2016 Dec 16;65(49):1405-1408
pubmed: 27977643
Pediatrics. 2011 Jan;127(1):19-27
pubmed: 21172992
MMWR Recomm Rep. 2014 Aug 29;63(RR-05):1-30
pubmed: 25167164
Vaccine. 2018 Jun 7;36(24):3498-3504
pubmed: 29752025
Acad Pediatr. 2018 Mar;18(2S):S37-S43
pubmed: 29502636
Cancer Epidemiol Biomarkers Prev. 2015 Nov;24(11):1673-9
pubmed: 26494764
Vaccine. 2016 Feb 24;34(9):1187-92
pubmed: 26812078
Int J Environ Res Public Health. 2018 Jan 23;15(2):
pubmed: 29360785
MMWR Morb Mortal Wkly Rep. 2018 Aug 24;67(33):918-924
pubmed: 30138307
MMWR Suppl. 2014 Sep 12;63(2):61-70
pubmed: 25208260
MMWR Morb Mortal Wkly Rep. 2011 Dec 23;60(50):1705-8
pubmed: 22189893
MMWR Morb Mortal Wkly Rep. 2018 Feb 09;67(5):156-157
pubmed: 29420458
Vaccine. 2011 Dec 9;30(1):14-20
pubmed: 22063390
Vaccine. 2018 Jun 27;36(28):4126-4133
pubmed: 29793895
Cancer Epidemiol Biomarkers Prev. 2016 Feb;25(2):309-17
pubmed: 26768989

Auteurs

Tanja Y Walker (TY)

Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Immunization Services Division.

Laurie D Elam-Evans (LD)

Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Immunization Services Division.

Charnetta L Williams (CL)

Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Immunization Services Division.

Benjamin Fredua (B)

Leidos Health, Inc., Reston, VA, USA.

David Yankey (D)

Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Immunization Services Division.

Lauri E Markowitz (LE)

Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Division of Viral Diseases, Atlanta, GA, USA.

Shannon Stokley (S)

Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Immunization Services Division.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH